AstraZeneca takes back autoimmune drug, sells rights to blood pressure treatments
The new arrangement will see Allergan still fund the development costs incurred by AstraZeneca
Company
AstraZeneca PLC
LON:AZN
AstraZeneca is one of the world's leading pharmaceutical companies, with a broad range of medicines designed to fight disease. AstraZeneca has over 67,000 empolyees and operates in over 100 countries with growing presence in important emerging markets.
1084 stories · page 31 of 55
AstraZeneca's Imfinzi granted orphan status as liver cancer treatment
Imfinzi and tremelimumab are now 'orphan drugs', meaning their development becomes a matter of public policy because they cure a rare disease
Mixed picture for UK pharma as AstraZeneca ‘top pick’ at Credit Suisse while GlaxoSmithKline knocked by Barclays downgrade
Credit Suisse said AZN's “top-line growth and underlying margin potential” made it the top firm in their assessments
AstraZeneca earnings to be hit by US$100mln write-down after trial stops
An independent data monitoring committee recommended to stop phase III of the trial on Epanova, which is still marketed in the US for other treatments
AstraZeneca weighs in with a double dose of good news
It has received a fast-track review of a diabetes drug while gaining approval for a blood treatment in China
AstraZeneca and Merck’s Lynparza drug approved by US FDA for pancreatic cancer
“Lynparza is now the only approved targeted medicine in biomarker-selected patients with advanced pancreatic cancer," said AstraZeneca's Dave Fredrickson.
AstraZeneca and Daiichi Sankyo's breast cancer treatment gets US approval
AstraZeneca and Daiichi Sankyo are exploring the further potential of Enhertu in HER2-breast cancer with three ongoing Phase III trials
AstraZeneca sells rights to breast, prostate cancer drugs for US$181mln
The FTSE 100-listed firm already sold commercial rights in the US in 2017, while now the drugs have lost exclusive rights in most countries in Europe and Africa
AstraZeneca’s presence in China boosted by Lynparza approval for ovarian cancer
Analysts said the prevalence of the BRCA-mutated ovarian cancer is higher in China and the approval will boost AstraZeneca’s already strong performance in the region
Addition by subtraction: AstraZeneca continues to slim down
It is selling the North American rights to its anti-psychotic products Seroquel and Seroquel XR. This is part of the Anglo-Swedish giant's focus on its core R&D portfolio and bunch blockbusters it owns
AstraZeneca cancer drug fast-tracked by the FDA
AZ wants to offer Imfinzi to people with late-stage small cell lung cancer
AstraZeneca's near-£100bn valuation is a vindication for Pascal Soriot
Since the Frenchman took the helm in October 2012, the drug giant's share price has increased by over 160%
AstraZeneca’s type-2 diabetes drug gets EU approval
Qtrilment, already approved in the US, comes in tablets and helps adults to control the level of sugar in the blood
AstraZeneca gets priority review in US for new NF1 treatment
The application is for the use of selumetinib in children aged three years and older.
AstraZeneca and the art of resurrecting failed drug candidates
Mereo and Evgen's drugs both stumbled as phase 2 trials yielded disappointing results, but an AstraZeneca-style turnaround could be around the corner
AstraZeneca’s lupus drug makes up for last year’s failure, faces competition
The FTSE 100-listed company said 47.8% of patients in phase III achieved a reduction of symptoms compared to 31.5% of those who used placebo
AstraZeneca anaemia drug data points to “yet another blockbuster”
Roxadustat could generate US$5bn in annual revenues, according to Shore Capital analysts
AstraZeneca to release data likely to move anaemia drug’s sales value by US$3.7bn, analysts say
Consensus is at US$1.3bn, although Shore Capital sees potential for up to US$5bn revenues if the US authorities do not deem necessary to include heart condition risks on the drug’s label
AstraZeneca to add $13bn product sales in next 5 years, says broker Liberum
Patent expiries have slowed Astra’s sales over the last few years, which retreated to $21bn in 2017, down from a peak of $34bn six years earlier
AstraZeneca hikes sales target after new drug successes
Product sales grew 16% in the third quarter, up from 12% in the first half of the year